The Economic Impact of Counterfeit Healthcare Products

Counterfeit healthcare products are a growing concern worldwide, affecting not only patient safety but also having significant economic repercussions. The proliferation of fake medications and medical devices undermines public health, drains economic resources, and imposes substantial costs on the healthcare industry. The importance of initiatives like TrueMed in mitigating these effects has transitioned from a luxury to a necessity.

The Scope of the Problem

The global trade in counterfeit pharmaceuticals is estimated to be worth between $200 billion and $431 billion annually, according to a report by the World Health Organization (WHO). The WHO reports that up tp 10% of medicines available globally could be counterfeit. This alarming figure represents a significant portion of the total pharmaceutical market, indicating the widespread nature of the problem. Counterfeit products can range from fake versions of brand-name drugs to substandard generic drugs, affecting a wide array of therapeutic categories and posing a substantial threat to public health.

Direct Economic Costs

Loss of Revenue for Legitimate Manufacturers: Counterfeit products siphon off revenue from legitimate manufacturers, leading to substantial financial losses. Pharmaceutical companies invest heavily in research and development (R&D) to bring new drugs to market. The presence of counterfeit products erodes their market share and profitability, which in turn affects their ability to fund future R&D projects. This loss of revenue can hinder the advancement of new and innovative treatments, ultimately affecting patient care and medical progress.

Increased Healthcare Costs: The presence of counterfeit drugs can lead to treatment failures, adverse reactions, and prolonged illnesses, resulting in additional medical expenses. According to the National Association of Boards of Pharmacy (NABP), counterfeit drugs contribute to an estimated $75 billion annual loss to the global economy due to increased healthcare costs and lost income from prolonged illness. Patients who unknowingly consume counterfeit drugs may experience worsened health conditions, leading to increased visits to healthcare facilities, additional diagnostic tests, and prolonged treatment regimens.

Costs to Regulatory and Enforcement Agencies: Government regulatory and enforcement agencies incur significant costs in their efforts to combat counterfeit healthcare products. These costs include monitoring and surveillance, investigation and enforcement actions, and public awareness campaigns. The resources allocated to these activities could otherwise be directed toward enhancing public health infrastructure and services.

Indirect Economic Costs

Impact on Employment: The economic burden extends to employment in the pharmaceutical industry. Legitimate manufacturers may face reduced sales and profits, leading to job losses and a decrease in investment in the workforce. Pharmaceutical companies may also be compelled to downsize or relocate operations to mitigate financial losses, resulting in further job displacements and economic instability in affected regions.

Strain on Healthcare Systems: Counterfeit products often lead to increased hospital admissions and longer hospital stays, putting a strain on healthcare systems. This additional burden diverts resources from other critical areas of healthcare, exacerbating the economic impact. For example, the need to treat complications arising from counterfeit drug use may lead to the postponement or cancellation of elective surgeries, creating a backlog of medical procedures and prolonging patient suffering.

Loss of Public Trust: The proliferation of counterfeit healthcare products undermines public trust in the healthcare system. Patients who fall victim to counterfeit drugs may lose confidence in their healthcare providers and the medications they are prescribed. This loss of trust can have far-reaching consequences, including reduced patient adherence to prescribed treatments and a general decline in public health outcomes. In all cases, patient or consumer is the ultimate loser and is suffering the consequences.

Global Trade and Economic Stability

Counterfeit healthcare products also disrupt global trade and economic stability. The infiltration of fake products into legitimate supply chains can damage the reputation of affected countries, reduce foreign investment, and harm international trade relations. The Organization for Economic Co-operation and Development (OECD) estimates that counterfeit goods, including pharmaceuticals, account for 3.3% of global trade. The economic ramifications of counterfeit products extend beyond the healthcare sector, affecting a wide range of industries and contributing to global economic instability.

The Role of TrueMed

TrueMed plays a crucial role in combating the economic impact of counterfeit healthcare products. By leveraging the Digital Forensic Lab to verify the authenticity of medications, TrueMed helps protect legitimate manufacturers’ revenues and ensures patients receive safe and effective treatments. TrueMed uses AI-driven, cutting-edge solutions that secure the pharmaceutical supply chain and prevent counterfeit products from reaching consumers without requiring any modifications to manufacturing.

TrueMed’s efforts enhance the global economy by reducing counterfeit products and their associated costs. By securing the pharmaceutical supply chain, TrueMed helps maintain public trust in healthcare systems and supports the industry’s economic stability. Prioritizing the fight against counterfeits safeguards public health and protects economic stability. TrueMed’s innovative solutions ensure patients receive genuine, safe treatments while bolstering the resilience of the pharmaceutical sector.

References

1. World Health Organization (WHO). (2017). “A Study on the Public Health and Socioeconomic Impact of Substandard and Falsified Medical Products.” WHO Report.
2. National Association of Boards of Pharmacy (NABP). (2020). “Counterfeit Drugs: Real Risks, Real Solutions.” NABP Report.
3. Organization for Economic Co-operation and Development (OECD). (2019). “Trends in Trade in Counterfeit and Pirated Goods.” OECD Report.

[Helsinki, 23MAY2024] TrueMed, the leading provider of anti-counterfeiting technology solutions for pharmaceuticals, announces its selection by a top 10 global pharmaceutical with medications spanning across oncology, cardiovascular, respiratory, vaccines, and more.

The partnership comes at a critical time, as counterfeit medications become increasingly sophisticated, posing a grave risk to patient safety worldwide. TrueMed’s advanced AI technology is uniquely capable of identifying the subtle indicators of counterfeit products, providing a level of detection precision that far exceeds traditional methods.

A key innovation of this collaboration is the decentralization of the authentication process. TrueMed’s technology will be deployed directly to frontline staff, empowering local investigators with the tools to quickly and accurately analyze suspicious samples. This approach not only expedites the investigative process but also significantly increases its efficiency and volume, ensuring a more robust defense against counterfeit medications.

Moreover, the adoption of TrueMed’s AI solutions by the leading pharmaceutical is expected to reduce the reliance on physical security features in packaging. This shift promises to lower costs and simplify packaging processes, aligning with environmental sustainability goals without compromising the integrity of the medications.

“This partnership isn’t just about technology; it’s about taking a stand for the safety of patients everywhere. The counterfeiters are getting smarter, using advanced methods to deceive us. That’s why it’s critical we outsmart them at every turn. Our AI isn’t just a collection of algorithms – it’s a powerful ally for the people on the ground, helping them catch what the naked eye can easily miss. Together, we’re making a real difference in the fight against fake meds.”, commented Jyrki Berg, CEO TrueMed.

For additional insights into TrueMed’s advanced AI-based anti-counterfeiting solutions, please visit www.truemedinc.com.

About TrueMed.

TrueMed is a leading provider of anti-counterfeiting technology solutions. The company’s AI-enabled platform uses cutting-edge technology to analyze and identify potential counterfeit products, allowing companies to quickly and efficiently protect their brands and their customers.

For more information, please visit truemedinc.com.
Contact: Tuomas Kannas, TrueMed, tuomas.kannas@truemedinc.com

In the complex ecosystem of healthcare, where the stakes involve life itself, the emergence of counterfeit pharmaceuticals as a global threat raises a critical question: who is ultimately responsible for keeping patients safe? While the integrity of pharmaceuticals is a cornerstone of patient safety, the reach of counterfeit medications across the globe challenges us to re-evaluate the roles and responsibilities within the healthcare supply chain.

The World Health Organization (WHO) has flagged counterfeit medications as a significant global issue, with estimates suggesting that up to 10% of medicines worldwide might be counterfeit, skyrocketing to 30% in some regions. The risk posed by counterfeit pharmaceuticals ranges from ineffective treatments to life-threatening complications, making the detection and prevention of such products paramount.

One might argue that the pharmaceutical companies, with their resources and expertise, are best positioned to lead the charge against counterfeits. After all, ensuring the authenticity of their products from production to patient should be a fundamental operation. Innovative technologies such as AI offer promising solutions to trace and verify the legitimacy of drugs throughout the supply chain, potentially outsmarting counterfeiters at their own game. But is the burden theirs alone?

Consider a scenario where counterfeit goods are shipped from ASIA to the US. The question arises: Who should be responsible for this? Some argue that manufacturers should verify their products’ authenticity, but this view doesn’t fully account for the role of distributors, who often profit by bringing in these fakes. For instance, if a distributor unknowingly imports counterfeit medications, they still make a profit, while the costs of dealing with these fakes could fall on the government or the original manufacturers.

Regulatory bodies and governments play a crucial role in establishing and enforcing standards and regulations to safeguard public health. Their authority allows them to implement measures that can significantly deter counterfeiters. However, regulations vary significantly across borders, and the effectiveness of enforcement can be inconsistent. In regions where oversight is weaker, counterfeit drugs proliferate, posing risks not just locally but also to travelers unaware of the dangers.

Healthcare providers are on the frontline, directly interacting with patients and medications. Their position enables them to be vigilant observers and educators, potentially identifying and warning against counterfeit medications. Yet, without the tools to verify authenticity or the knowledge of the prevalence of counterfeits, their ability to protect patients is limited.

Patients themselves, often the most vulnerable and least equipped to identify counterfeit medications, are thrust into a situation where they must trust the integrity of the drugs they consume. Educating patients on the risks of counterfeit drugs and empowering them to ask questions about the source of their medications can be a vital step in patient safety. But again, the question arises – should the onus be on them?

The answer to who bears the ultimate responsibility for protecting patients from counterfeit pharmaceuticals is not straightforward. It’s a shared responsibility, requiring a multifaceted approach that involves pharmaceutical companies, regulatory bodies, healthcare providers, even distributors and finally patients themselves. Each stakeholder in the healthcare ecosystem must play their part, with pharmaceutical companies innovating to stay ahead of counterfeiters, governments enforcing strict regulations, healthcare providers educating and being vigilant, and patients being informed and cautious.

Safeguarding against counterfeit pharmaceuticals is a collective battle, one that demands collaboration, innovation, and vigilance from all corners of the healthcare system. Only through a united front can we hope to protect patients from the dangers of counterfeit medications, ensuring the safety and integrity of the pharmaceuticals upon which so many rely.

In the ever-evolving landscape of global commerce, a silent but escalating battle rages on. The protagonists? Brands, consumers, and regulatory authorities. Their adversary? An increasingly sophisticated network of counterfeiters, whose capabilities have surged with the aid of advanced technologies. This conflict has spread far beyond the realms of luxury fashion, electronics, pharmaceuticals, and a myriad of consumer goods. As we navigate through 2024, it’s evident that the counterfeit market has not only grown in volume but in the finesse of its deceptions.

The Rise of Sophistication

Gone are the days when counterfeit goods were easily spotted, relegated to the shady corners of the internet or the dubious street vendor. Today’s fakes are a different breed altogether, crafted with such precision that they blur the lines between authenticity and imitation. This leap in quality owes much to advancements in technology and manufacturing techniques, which have armed counterfeiters with the tools to mimic legitimate products with alarming accuracy.

The Twin Pillars of Counterfeit Evolution

What has enabled counterfeiters to make such a significant advance? The root of this progression can be traced back to the exploitation of technology and the emergence of artificial intelligence (AI). Firstly, there’s the issue of access to specialized production tools, such as machines for making pills, which were previously available only to verified entities but have now been spotted for sale to the general public on platforms like eBay. Additionally, the illicit access to or mishandling of original print files facilitates the production of highly convincing fakes. Secondly, AI has emerged as a groundbreaking tool in the arsenal of counterfeiters, allowing them to create imitations with an accuracy that was previously deemed impossible. This has led to a remarkable increase in the quality of counterfeit goods, highlighting a quiet yet rapid evolution in the methods of counterfeiting.

Impact on Brands and Consumers

This surge in counterfeit sophistication poses dire consequences for brands and consumers alike. For businesses, the infiltration of fakes not only erodes brand integrity but translates into significant financial hemorrhage. Consumers, on the other hand, face risks that transcend monetary loss. Counterfeit pharmaceuticals may endanger health, fake electronics could flout safety standards, and the list goes on. The stakes are undeniably high, underscoring the urgent need for a robust response.

The Future Battlefront: Anticipating Trends and Preparing Defenses

As counterfeiters grow more adept, the onus is on authorities and industries to stay one step ahead. This means not allowing the technological gap to widen but instead investing in the latest defensive technologies. The battle against counterfeits is not lost; it simply demands a shift in strategy. By leveraging AI and other forward-thinking technologies, we can build a more resilient defense against the counterfeit onslaught.

A Call to Arms: Leveraging AI for Defense

In the face of such sophisticated threats, mere vigilance is insufficient. What’s required is a comprehensive strategy that not only anticipates future trends but actively counters them. AI, with its vast potential for detecting and distinguishing between genuine and counterfeit products, stands at the forefront of this battle. It’s not just about fighting back; it’s about outsmarting the counterfeiters at their own game.

The rise of counterfeit sophistication in 2024 is a call to action for brands, consumers, and authorities alike. While the challenge is formidable, it is not insurmountable. By embracing AI and advanced technologies like the TrueMed Digital Forensic Lab, we can turn the tide against counterfeiters, safeguarding both brand integrity and consumer safety. The future of this battle will be shaped by our willingness to invest in and adopt innovative solutions. The time to act is now; the cost of inaction is too great.

The global health landscape is increasingly challenged by the rise of counterfeit medications. Far from being just a financial problem, these illicit drugs pose significant health hazards and broadly destabilize the foundation of healthcare systems internationally.

Understanding Counterfeit Medications

Counterfeit medications are unauthorized replicas of genuine drugs, which can include not just incorrect or harmful ingredients but also simply just water, especially in vials. These substances lack the therapeutic efficacy of their legitimate counterparts, exacerbating health conditions by failing to provide appropriate treatment. Moreover, this exposes patients to potentially toxic substances, further endangering their health and safety. The global market for counterfeit pharmaceuticals was estimated to be worth $200 billion annually, making it one of the most lucrative sectors of the global trade in illegally copied goods, according to the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA).

The World Health Organization (WHO) has identified that roughly 1 in 10 medical products in low- and middle-income countries is either substandard or falsified. These counterfeit products span a wide range of medical categories, including critical medications like anti-malarial and antibiotics. The WHO also reports that counterfeit medication is responsible for the deaths of an estimated 1 million people annually worldwide.

A Global Concern

Despite having one of the safest drug supplies in the world, even the United States is not immune to the counterfeit drug issues. The FDA emphasizes that illegal online pharmaceutical sales are a primary conduit for counterfeit medicines entering the American market. The National Association of Boards of Pharmacy (NABP) reported that out of thousands of online pharmacies reviewed, over 95% do not comply with legal and safety standards, posing a significant risk for consumers seeking medication online. This digital loophole poses significant challenges to regulatory and enforcement agencies. The Centers for Disease Control and Prevention (CDC) has observed a concerning trend in drug overdose deaths linked to counterfeit pills. These counterfeit pills, often laced with potent substances like fentanyl, have contributed to a sharp rise in overdose fatalities.

Countries such as Brazil, Argentina, and Colombia have reported significant seizures of counterfeit drugs, highlighting the widespread nature of this problem. These illicit medications range from fake versions of popular painkillers to counterfeit treatments for life-threatening conditions like cancer and heart disease. The open borders and varied regulatory standards across South American countries facilitate the entry and distribution of counterfeit drugs, complicating efforts to curb their spread.

Asia faces a unique set of challenges in the fight against counterfeit medications, partly due to its vast size, population diversity, and disparities in healthcare infrastructure. Countries like China and India, with their large pharmaceutical industries, are both significant sources and victims of counterfeit drugs. These counterfeit medications not only undermine public health but also damage the reputation of legitimate manufacturers. The region has seen everything from counterfeit antivirals and antibiotics to fake vaccines, especially during the COVID-19 pandemic, which has exacerbated the problem. Efforts to tackle this issue in Asia include stricter regulatory measures, cross-border collaboration, and the adoption of advanced technologies for drug verification and tracking. However, the sheer scale of the counterfeit drug trade in Asia demands continuous and coordinated efforts at both national and international levels to protect consumers and ensure the safety of the pharmaceutical supply chain.

Europe also grapples with the complexities of counterfeit drugs, although the prevalence is lower compared to other regions, thanks to stringent regulatory frameworks and effective enforcement. However, the rise of online pharmacies has opened a new front in the fight against fake drugs, with European consumers at risk of purchasing counterfeit medications from illegitimate websites. The European Union has implemented several measures to safeguard the pharmaceutical supply chain, including the Falsified Medicines Directive (FMD) and the European Medicines Verification System (EMVS), which aims to ensure the authenticity of medicinal products. Despite these efforts, the problem persists, with incidents of counterfeit cancer medications, antibiotics, and erectile dysfunction pills being reported in various European countries. Collaboration between national regulatory agencies, healthcare providers, and the pharmaceutical industry is crucial to addressing the issue, along with continued public education on the risks of buying medicines from unverified sources.

A Beacon of Hope 

Combating counterfeit medications demands a multifaceted approach. Strengthening international cooperation, enhancing regulatory frameworks, and raising public awareness are critical steps. Technological innovations, including sophisticated drug authentication methods, can play a pivotal role in identifying and eliminating counterfeit drugs from the market.

The counterfeit medication crisis is a complex and pervasive challenge with far-reaching implications for global health. To effectively mitigate its impact, concerted efforts are required from governments, healthcare providers, regulatory agencies, and the public, alongside advanced technologies like the Digital Forensic Lab developed by TrueMed. TrueMed’s innovative AI-powered solutions play a crucial role in this battle, offering effective tools for detecting counterfeit medications. By uniting in this fight, leveraging both policy and technological advancements, we can strive to protect public health and maintain the integrity of the global pharmaceutical supply chain.

Sources:

World Health Organization: Substandard and falsified medical products https://www.who.int/news-room/fact-sheets/detail/substandard-and-falsified-medical-products

U.S. Food and Drug Administration: Counterfeit Medicine https://www.fda.gov/drugs/buying-using-medicine-safely/counterfeit-medicine

Centers for Disease Control and Prevention: Drug Overdose Deaths with Evidence of Counterfeit Pill Use — United States, July 2019–December 2021 https://www.cdc.gov/mmwr/volumes/71/wr/mm7114a1.htm

UK Government: Counterfeit medicines: what pharmacists should know https://www.gov.uk/government/publications/counterfeit-medicines-what-pharmacists-should-know

[Helsinki, 06FEB2024] TrueMed, the leading provider of anti-counterfeiting technology solutions for pharmaceuticals, announces a strategic collaboration with an additional global leader in pharmaceuticals and healthcare. An additional top 10 pharmaceutical company has joined forces with TrueMed, reflecting a shared commitment to combat the surge of counterfeit and illicit medicines. Leveraging TrueMed’s Digital Forensic Lab and advanced AI technology, the collaboration is poised to make a meaningful impact on patient safety by effectively detecting and addressing counterfeit drugs.

TrueMed’s innovative AI platform, utilizing mobile phone cameras, artificial intelligence to reach high accuracy, and data analytics, is at the forefront of accurately identifying counterfeit pharmaceuticals, strengthening the pharmaceutical company’s capacity for investigation and response. This technology is integral to forensic analyses and seamlessly integrates with existing security processes, streamlining the fight against fake medications without necessitating costly manufacturing changes.

TrueMed was chosen as a partner for its expertise and commitment to the safety and integrity of medicines. This collaboration is centered on enhancing laboratory capabilities to efficiently identify and investigate counterfeit drugs. The partnership aims to guarantee the delivery of safe and authentic treatments, addressing a crucial need in healthcare for dependable and effective medication.

Jyrki Berg, CEO of TrueMed, remarked on the significance of this collaboration, noting, “Our strategic alliance with this pharmaceutical leader is a significant step towards directly addressing the challenge of counterfeit drugs. Through this partnership, we’re employing the latest technologies and drawing on deep industry expertise to significantly advance patient safety globally.”

This partnership reflects a shared goal in the pharmaceutical industry to innovate and improve patient care. It shows how AI is important in keeping healthcare safe and marks a significant step forward in working together to protect health worldwide.

For additional insights into TrueMed’s advanced AI-based anti-counterfeiting solutions, please visit www.truemedinc.com.

About TrueMed.  

TrueMed is a leading provider of anti-counterfeiting technology solutions. The company’s AI-enabled platform uses cutting-edge technology to analyze and identify potential counterfeit products, allowing companies to quickly and efficiently protect their brands and their customers.

For more information, please visit truemedinc.com.
Contact: Tuomas Kannas, TrueMed, tuomas.kannas@truemedinc.com

TrueMed enhances field investigations with advanced AI-powered counterfeit detection.   

[Helsinki, 10JAN2024] – TrueMed, the leading provider of anti-counterfeiting technology solutions, has announced its selection by a leading global pharmaceutical company to enhance the fight against counterfeit medications. This collaboration represents a significant commitment to ensuring the safety and integrity of its extensive product portfolio, reinforcing both companies’ dedication to patient safety and brand protection. 

The initiative comes in response to the increasing sophistication of counterfeit medications, which pose a risk to patient health and the overall trust in healthcare. By incorporating TrueMed’s advanced detection technologies, the pharmaceutical company aims to significantly improve the accuracy and efficiency of identifying fake drugs within the market. TrueMed’s system offers a substantial improvement over traditional detection methods, which often rely on manual inspection and can miss high-quality counterfeits. 

As part of this collaboration, field investigators will be equipped with TrueMed’s cutting-edge tools, enhancing their ability to identify and report counterfeit products. This technology reduces the need for extensive training and experience traditionally required for counterfeit detection, allowing for a more agile and effective response to the ever-evolving threat of fake medications. 

“The increase in counterfeiter sophistication demands a rigorous response, and we are committed to that challenge,” said Jyrki Berg, CEO of TrueMed. “Our digital laboratory’s technology provides timely and accurate detection, supporting the investigators in unprecedented ways. Our goal is to not just respond to counterfeiting trends but to actively define higher standards for product safety and authenticity.” 

TrueMed simplifies the field inspection process by allowing less skilled investigators to conduct effective work. The technology takes over complex identification tasks, enabling more widespread and cost-effective investigations without the need for extensive training or experience. This approach helps scale up operations efficiently, making field inspections more accessible. 

For more information about TrueMed’s advanced AI-counterfeit detection solutions, please visit www.truemedinc.com. 

About TrueMed.  
 
TrueMed is a leading provider of anti-counterfeiting technology solutions. The company’s AI-enabled platform uses cutting-edge technology to analyze and identify potential counterfeit products, allowing companies to quickly and efficiently protect their brands and their customers. 

For more information, please visit truemedinc.com. 
Contact: Tuomas Kannas, TrueMed, tuomas.kannas@truemedinc.com 

[Helsinki, 13 DEC 2023] – TrueMed, the leading provider of anti-counterfeiting technology solutions, announces its selection by a top 10 global pharmaceutical company to enhance their counterfeit detection capabilities. This partnership marks a significant step in the digitalization and modernization of laboratory processes in the fight against counterfeit drugs.

“Counterfeiters are becoming more sophisticated, and we’re determined to outsmart them at every turn,” asserts Jyrki Berg, CEO of TrueMed. “Our lab’s advanced capabilities in delivering instant, accurate results are in line with the pharmaceutical company’s goals of innovation and proactive defense. We’re not just keeping pace with counterfeiters; we’re setting the pace, ensuring that patient safety and product authenticity remain uncompromised.”

Featuring AI and image analysis for instant product verification, the Digital Forensic Lab enables investigators to perform additional checks without physical shipping, avoiding extra logistical costs. Its ability to efficiently identify previously known counterfeit products minimizes the need for manual validations.

The Digital Forensic Lab’s complements the pharmaceutical company’s objective of employing cutting-edge tools to safeguard its products. By integrating this lab into their processes, the company is better equipped to handle the increasing complexity of counterfeit drug cases, ensuring that their response is not only swift but also deeply integrated into their broader operational and strategic framework.

The partnership between TrueMed’s Digital Forensic Lab and the pharmaceutical company not only signifies a milestone in enhancing drug authenticity and safety but also brings remarkable efficiency gains. By reducing each counterfeit analysis from 4 hours to just 15 minutes, an impressive 94%-time savings.

Jyrki Berg, CEO of TrueMed, remarks, “This partnership is transformative. By integrating our advanced forensic capabilities with strategic foresight, we’re disrupting the approach to counterfeit drug analysis, ushering in more secure and reliable pharmaceutical practices.”

For more information about TrueMed’s advanced AI-counterfeit detection solutions, please visit www.truemedinc.com.

About TrueMed.

TrueMed is a leading provider of anti-counterfeiting technology solutions. The company’s AI-enabled platform uses cutting-edge technology to analyze and identify potential counterfeit products, allowing companies to quickly and efficiently protect their brands and their customers.

For more information, please visit truemedinc.com.
Contact: Tuomas Kannas, TrueMed, tuomas.kannas@truemedinc.com

[Helsinki, 27NOV2023] – TrueMed, the leading provider of anti-counterfeiting technology solutions, is proud to launch its cutting-edge Digital Forensic Lab, a significant expansion in its suite of counterfeit detection solutions. This innovative solution delivers advanced digital forensic analysis, significantly accelerating the process of precise and thorough investigation in complex counterfeit cases. 

“As counterfeiters become more sophisticated in their methods, it’s imperative that our technology evolves at an even faster pace to detect them.” said Jyrki Berg, CEO of TrueMed  “By providing instant results and comprehensive case reporting, we empower laboratories and brand holders with unprecedented speed and accuracy in product verification.” 

The Digital Forensic Lab integrates image capture with AI and machine learning for instant product verification. The system also allows investigators to conduct further verifications without the need for physical shipping, thereby circumventing additional logistical and third-party expenses. A notable feature of the Digital Forensic Lab is its capability to efficiently manage and recognize previously identified counterfeit products, reducing the necessity for repeated validations.  

“Our Digital Forensic Lab eliminates the need for lengthy physical lab tests and manual reporting as all data is automatically centralized” added Jyrki. “This ensures that brand holders and investigators have real-time, actionable insights at their fingertips.” 

TrueMed’s Digital Forensic Lab, now available to healthcare organizations, pharmaceutical companies, and regulatory bodies, offers a reliable solution for identifying counterfeit products without needing a physical lab. This cost-effective tool complements existing labs, providing enhanced efficiency and savings while ensuring product authenticity and safety. 

For additional details please visit our website at https://truemedinc.com/digital-forensic-lab/ 

About TrueMed 

TrueMed is a leading provider of anti-counterfeiting technology solutions. The company’s AI-enabled platform uses cutting-edge technology to analyze and identify potential counterfeit products, allowing companies to quickly and efficiently protect their brands and their customers.

For more information, please visit truemedinc.com.
Contact: Tuomas Kannas, TrueMed, tuomas.kannas@truemedinc.com 

https://www.youtube.com/watch?v=IgxMzdsA4ek

Tech-Empowered Labs

Tired of the old-fashioned, time-consuming lab processes? Say hello to TrueMed, your gateway to the digital future of laboratory services.

Learn More